Skip to main content
SpringerLink
Log in

Rapid Production of Synthetic Influenza Vaccines

  • Chapter
  • First Online:
Influenza Pathogenesis and Control - Volume II

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 386))

Abstract

The strain composition of influenza vaccines must be changed regularly to track influenza virus antigenic evolution. During outbreaks with pandemic potential, strain changes are urgent. The systems for accomplishing vaccine strain changes have required the shipment of viruses and other biological materials around the globe, with delays in vaccine availability, and have used legacy techniques of egg-based virus cultivation, resulting in vaccine mismatches. In collaboration with Synthetic Genomics Vaccines Inc. and the US Biomedical Advanced Research and Development Authority, Novartis has developed a synthetic approach to influenza vaccine virus generation. Synthetic influenza vaccine viruses and mammalian cell culture technology promise influenza vaccines that match circulating influenza strains more closely and are delivered in greater quantities, more rapidly than vaccines produced by conventional technologies. These new technologies could yield an improved influenza vaccine response system in which viral sequence data from many sources are posted on the Internet, are downloaded by vaccine manufacturers, and are used to rescue multiple, attenuated vaccine viruses directly on high yielding backbones. Elements of this system were deployed in the response to the 2013 H7N9 influenza outbreak in China. The result was the production, clinical testing, and stockpiling of an H7N9 vaccine before the second wave of the outbreak struck at the end of 2013. Future directions in synthetic influenza vaccine technology include the automation of influenza virus rescue from sequence data and the merger of synthetic and self-amplifying mRNA vaccine technologies. The result could be a more robust and effective influenza vaccine system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdelwhab EM, Veits J, Mettenleiter TC (2014) Prevalence and control of H7 avian influenza viruses in birds and humans. Epidemiol Infect 142:896–920. doi:10.1017/S0950268813003324

    Article  CAS  PubMed  Google Scholar 

  • Advisory Committee on Immunization Practices (2013) Prevention and control of influenza with vaccines: interim recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. MMWR Morb Mortal Wkly Rep 62:356

    Google Scholar 

  • Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B (2009) Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27:5998–6003. doi:10.1016/j.vaccine.2009.07.079

  • Ambrose CS, Levin MJ (2012) The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 8:81–88. doi:10.4161/hv.8.1.17623

    Article  PubMed Central  PubMed  Google Scholar 

  • Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesa-thasan N (2014) A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 6:234ra55. doi:10.1126/scitranslmed.3008761

  • Bedford T, Suchard MA, Lemey P, Dudas G, Gregory V, Hay AJ, McCauley JW, Russell CA, Smith DJ, Rambaut A (2014) Integrating influenza antigenic dynamics with molecular evolution. Elife 3: e01914. doi: 10.7554/eLife.01914

  • Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK, Marshfield Influenza Study Group (2009) Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 199:159–167. doi: 10.1086/595861

  • Berns KI, Casadevall A, Cohen ML, Ehrlich SA, Enquist LW, Fitch JP, Franz DR, Fraser-Liggett CM, Grant CM, Imperiale MJ, Kanabrocki J, Keim PS, Lemon SM, Levy SB, Lumpkin JR, Miller JF, Murch R, Nance ME, Osterholm MT, Relman DA, Roth JA, Vidaver AK (2012) Policy: adaptations of avian flu virus are a cause for concern. Nature 482:153–154. doi:10.1038/482153a

    CAS  PubMed  Google Scholar 

  • Bibby K (2013) Metagenomic identification of viral pathogens. Trends Biotechnol 31:275–279. doi:10.1016/j.tibtech.2013.01.016

    Article  CAS  PubMed  Google Scholar 

  • Bogner P, Capua I, Cox NJ, Lipman DJ (2006) A global initiative on sharing avian flu data. Nature 442:981–981. doi:10.1038/442981a

    Article  CAS  Google Scholar 

  • Centers for Disease Control and Prevention (2004a) Updated interim influenza vaccination recommendations–2004–05 influenza season. MMWR Morb Mortal Wkly Rep 53:1183–1184

    Google Scholar 

  • Centers for Disease Control and Prevention (2004b) Preliminary assessment of the effectiveness of the 2003–04 inactivated influenza vaccine–Colorado, December 2003. MMWR Morb Mortal Wkly Rep 53:8–11

    Google Scholar 

  • Centers for Disease Control and Prevention (2009) Swine influenza A (H1N1) infection in two children–Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep 58:400–402

    Google Scholar 

  • Centers for Disease Control and Prevention (2013) Interim adjusted estimates of seasonal influenza vaccine effectiveness—United States, Feb 2013. MMWR Morb Mortal Wkly Rep 62:119–123

    Google Scholar 

  • Chung N, Locco L, Huff KW, Bartz S, Linsley PS, Ferrer M, Strulovici B (2008) An efficient and fully automated high-throughput transfection method for genome-scale siRNA screens. J Biomol Screen 13:142–148. doi:10.1177/1087057107312032

    Article  CAS  PubMed  Google Scholar 

  • Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I (2009a) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361:2424–2435. doi:10.1056/NEJMoa0907650

  • Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I (2009b) Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine—preliminary report. N Engl J Med 361. doi:10.1056/NEJMoa0907650

  • Committee for Proprietary Medicinal Products (2004) Guideline on submission of marketing authorization for pandemic influenza vaccines through the centralized procedure. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003815.pdf

  • Committee on Standard Serological Procedures in Influenza Studies (1950) Agglutination-inhibition test proposed as a standard of reference in influenza diagnostic studies. J Immunol 65:347–353

    Google Scholar 

  • Cox NJ (2013) Information for the vaccines and related biological products advisory committee, CBER, FDA. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM343326.pptx

  • Cox NJ (2014) Information for the vaccines and related biological products Advisory Committee, CBER, FDA. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM390700.pptx

  • Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ (2014) Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 11:885–899. doi:10.1517/17425247.2014.901308

    PubMed  Google Scholar 

  • Dormitzer PR, Tsai TF, Del Giudice G (2012) New technologies for influenza vaccines. Hum Vaccin Immunother 8:45–58. doi:10.4161/hv.8.1.18859

    Article  CAS  PubMed  Google Scholar 

  • Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, Alperovich N, Barro M, Brown DM, Craig S, Dattilo BM, Denisova EA, De Souza I, Eickmann M, Dugan VG, Ferrari A, Gomila RC, Han L, Judge C, Mane S, Matrosovich M, Merryman C, Palladino G, Palmer GA, Spencer T, Strecker T, Trusheim H, Uhlendorff J, Wen Y, Yee AC, Zaveri J, Zhou B, Becker S, Donabedian A, Mason PW, Glass JI, Rappuoli R, Venter JC (2013) Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 5:185ra68. doi:10.1126/scitranslmed.3006368

  • Elsliger MA, Deacon AM, Godzik A, Lesley SA, Wooley J, Wuthrich K, Wilson IA (2010) The JCSG high-throughput structural biology pipeline. Acta Crystallogr Sect F Struct Biol Cryst Commun 66:1137–1142. doi:10.1107/S1744309110038212

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • FDA, CBER (2010) Guidance for industry. Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM202439.pdf

  • Fidler DP (2008) Influenza virus samples, international law, and global health diplomacy. Emerg Infect Dis 14:88–94. doi:10.3201/eid1401.070700

    Article  PubMed Central  PubMed  Google Scholar 

  • Finelli L (2013) Influenza activity update. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM343328.pptx

  • Francis T, Salk JE, Quilligan JJ (1947) Experience with vaccination against influenza in the spring of 1947: a preliminary report. Am J Public Health Nations Health 37:1013–1016

    Article  CAS  PubMed Central  Google Scholar 

  • Fries LF, Smith GE, Glenn GM (2013) A recombinant virus-like particle influenza A (H7N9) vaccine. N Engl J Med 369:2564–2566. doi:10.1056/NEJMc1313186

    Article  CAS  PubMed  Google Scholar 

  • Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y (2013) Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368:1888–1897. doi:10.1056/NEJMoa1304459

    Article  CAS  PubMed  Google Scholar 

  • Garfinkel MS, Endy D, Epstein GL, Friedman RM (2007) Synthetic genomics options for governance. Biosecur Bioterror 5:359–362. doi:10.1089/bsp.2007.0923

    Article  PubMed  Google Scholar 

  • Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O’Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 109:14604–14609. doi:10.1073/pnas.1209367109

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ghendon YZ, Polezhaev FI, Lisovskaya KV, Medvedeva TE, Alexandrova GI, Klimov AI (1984) Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants. Infect Immun 44:730–733

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R, Assad-Garcia N, Andrews-Pfannkoch C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, Venter JC (2010a) Creation of a bacterial cell controlled by a chemically synthesized genome. Science 329:52–56. doi:10.1126/science.1190719

    Article  CAS  PubMed  Google Scholar 

  • Gibson DG, Smith HO, Hutchison CA 3rd, Venter JC, Merryman C (2010b) Chemical synthesis of the mouse mitochondrial genome. Nat Methods 7:901–903. doi:10.1038/nmeth.1515

    Article  CAS  PubMed  Google Scholar 

  • Gomila RC, Suphaphiphat P, Judge C, Spencer T, Ferrari A, Wen Y, Palladino G, Dormitzer PR, Mason PW (2013) Improving influenza virus backbones by including terminal regions of MDCK-adapted strains on hemagglutinin and neuraminidase gene segments. Vaccine 31:4736–4743. doi:10.1016/j.vaccine.2013.08.026

    Article  CAS  PubMed  Google Scholar 

  • Grohskopf L (2011) U.S. influenza surveillance, VRBPAC meeting. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM246396.pptx

  • Grohskopf L (2012) U.S. Influenza surveillance, 2011–2012 season. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM297004.pptx

  • Harvey R, Guilfoyle KA, Roseby S, Robertson JS, Engelhardt OG (2011) Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules. J Virol 85:6086–6090. doi:10.1128/JVI.00096-11

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini: D, Maione D, Qi Z-Q, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Venter JC, Dormitzer PR, Rappuoli R, Geall AJ (2013) Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microb Infect 2:e52

    Google Scholar 

  • Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, Fouchier RA (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336:1534–1541. doi:10.1126/science.1213362

    Article  CAS  PubMed  Google Scholar 

  • HHS, USDA (2012a) Title 7: Agriculture. Part 331—possession, use, and transfer of select agents and toxins. In: US Departments of Health and Human Services (HHS) and Agriculture (USDA) 7 C.F.R part 331

    Google Scholar 

  • HHS, USDA (2012b) Title 9: animals and animal products. Part 121—possession, use, and transfer of select agents and toxins. In: US Departments of Health and Human Services (HHS) and Agriculture (USDA) 9 C.F.R part 121

    Google Scholar 

  • HHS, USDA (2012c) Title 42: public health. Part 73—select agents and toxins. In: US Departments of Health and Human Services (HHS) and Agriculture (USDA) 42 C.F.R part 73

    Google Scholar 

  • Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 97:6108–6113. doi:10.1073/pnas.100133697

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420–428. doi:10.1038/nature10831

    CAS  PubMed Central  PubMed  Google Scholar 

  • Katz JM, Wang M, Webster RG (1990) Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 64:1808–1811

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kilbourne ED (1969) Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ 41:643–645

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, Xu H, Takashita E, Tashiro M, Takao S, Yano T, Suga T, Kawakami C, Yamamoto M, Kajiyama K, Saito H, Shimada S, Watanabe S, Aoki S, Taira K, Kon M, Lin JH, Odagiri T (2012) Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol 19:897–908. doi:10.1128/CVI.05726-11

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Landry N, Ward BJ, Trepanier S, Montomoli E, Dargis M, Lapini G, Vezina LP (2010) Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5:e15559. doi:10.1371/journal.pone.0015559

  • Lemey P, Rambaut A, Bedford T, Faria N, Bielejec F, Baele G, Russell CA, Smith DJ, Pybus OG, Brockmann D, Suchard MA (2014) Unifying viral genetics and human transportation data to predict the global transmission dynamics of human influenza H3N2. PLoS Pathog 10:e1003932. doi:10.1371/journal.ppat.1003932

    Article  PubMed Central  PubMed  Google Scholar 

  • Maassab HF, Francis T Jr, Davenport FM, Hennessy AV, Minuse E, Anderson G (1969) Laboratory and clinical characteristics of attenuated strains of influenza virus. Bull World Health Organ 41:589–594

    CAS  PubMed Central  PubMed  Google Scholar 

  • Marsh GA, Tannock GA (2005) The role of reverse genetics in the development of vaccines against respiratory viruses. Expert Opin Biol Ther 5:369–380. doi:10.1517/14712598.5.3.369

    Article  CAS  PubMed  Google Scholar 

  • Ndifon W, Dushoff J, Levin SA (2009) On the use of hemagglutination-inhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness. Vaccine 27:2447–2452. doi:10.1016/j.vaccine.2009.02.047

    Article  CAS  PubMed  Google Scholar 

  • Nicolson C, Major D, Wood JM, Robertson JS (2005) Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23:2943–2952. doi:10.1016/j.vaccine.2004.08.054

    Article  CAS  PubMed  Google Scholar 

  • Onions D, Egan W, Jarrett R, Novicki D, Gregersen JP (2010) Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 38:544–551. doi:10.1016/j.biologicals.2010.04.003

    Article  CAS  PubMed  Google Scholar 

  • Orsi A, Ansaldi F, de Florentiis D, Ceravolo A, Parodi V, Canepa P, Coppelli M, Icardi G, Durando P (2013) Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines. Hum Vaccin Immunother 9:582–590

    Google Scholar 

  • Rappuoli R, Dormitzer PR (2012) Influenza: options to improve pandemic preparation. Science 336:1531–1533. doi:10.1126/science.1221466

    Article  CAS  PubMed  Google Scholar 

  • Rines DR, Tu B, Miraglia L, Welch GL, Zhang J, Hull MV, Orth AP, Chanda SK (2006) High-content screening of functional genomic libraries. Methods Enzymol 414:530–565. doi:10.1016/S0076-6879(06)14028-8

    Article  CAS  PubMed  Google Scholar 

  • Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z, Chen LM, O’Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO (2011) The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29:1836–1843. doi:10.1016/j.vaccine.2010.12.044

    Article  CAS  PubMed  Google Scholar 

  • Roth B, Mohr H, Enders M, Garten W, Gregersen JP (2012) Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses. Vaccine 30:517–522. doi:10.1016/j.vaccine.2011.11.063

    Article  CAS  PubMed  Google Scholar 

  • Schild GC, Wood JM, Newman RW (1975) A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 52:223–231

    CAS  PubMed Central  PubMed  Google Scholar 

  • Schild GC, Oxford JS, de Jong JC, Webster RG (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303:706–709

    Article  CAS  PubMed  Google Scholar 

  • Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Avian flu: influenza virus receptors in the human airway. Nature 440:435–436

    Article  CAS  PubMed  Google Scholar 

  • Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y (2014) Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 9:e92153. doi:10.1371/journal.pone.0092153

    Article  PubMed Central  PubMed  Google Scholar 

  • Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Fouchier RA (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305:371–376. doi:10.1126/science.1097211

    Article  CAS  PubMed  Google Scholar 

  • Steinhauer DA (1999) Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 258:1–20. doi:10.1006/viro.1999.9716

    Article  CAS  PubMed  Google Scholar 

  • Stevens J, Chen LM, Carney PJ, Garten R, Foust A, Le J, Pokorny BA, Manojkumar R, Silverman J, Devis R, Rhea K, Xu X, Bucher DJ, Paulson JC, Cox NJ, Klimov A, Donis RO (2010) Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J Virol 84:8287–8299. doi:10.1128/JVI.00058-10

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Stohr K (2013) Influenza vaccine production. In: Webster RG, Monto AS, Braciale TJ, Lamb RA (eds) Textbook of influenza, 2nd edn. Wiley, West Sussex, pp 352–372

    Google Scholar 

  • Stohr K (2014) Perspective: Ill prepared for a pandemic. Nature 507:S20–S21

    Article  PubMed  Google Scholar 

  • Strecker T, Uhlendorff J, Diederich S, Lenz-Bauer C, Trusheim H, Roth B, Kolesnikova L, Aepinus C, Dornow R, Gerlach J, Matrosovich M, Valley U, Eickmann M, Becker S (2012) Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens. Clin Chem Lab Med 50:1275–1279. doi:10.1515/cclm-2011-0650

    Article  CAS  PubMed  Google Scholar 

  • Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, Matsuoka Y (2003) Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305:192–200

    Article  CAS  PubMed  Google Scholar 

  • Suphaphiphat P, Keiner B, Trusheim H, Crotta S, Tuccino AB, Zhang P, Dormitzer PR, Mason PW, Franti M (2010) Human RNA polymerase I-driven reverse genetics for influenza a virus in canine cells. J Virol 84:3721–3725. doi:10.1128/JVI.01925-09

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tizzoni M, Bajardi P, Poletto C, Ramasco JJ, Balcan D, Goncalves B, Perra N, Colizza V, Vespignani A (2012) Real-time numerical forecast of global epidemic spreading: case study of 2009 A/H1N1pdm. BMC Med 10:165. doi:10.1186/1741-7015-10-165

    Article  PubMed Central  PubMed  Google Scholar 

  • Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M (2011) Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 29:7733–7739. doi:10.1016/j.vaccine.2011.07.128

    Article  CAS  PubMed  Google Scholar 

  • Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M (2013) Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 11:153. doi:10.1186/1741-7015-11-153

    Article  PubMed Central  PubMed  Google Scholar 

  • US Food and Drug Administration (2007) Guidance—emergency use authorization of medical products. http://www.fda.gov/RegulatoryInformation/Guidances/ucm125127.htm

  • USDA (2004) Data necessary to consider select agent exclusion requests attenuated strains of highly pathogenic avian influenza (HPAI) viruses. http://www.selectagents.gov/resources/DataRequirementsforExclusionConsideration.pdf

  • Venter JC (2013) Life at the speed of light. Viking, The Penguin Group, New York

    Google Scholar 

  • Wang Z, Duke GM (2007) Cloning of the canine RNA polymerase I promoter and establishment of reverse genetics for influenza A and B in MDCK cells. Virol J 4:102. doi:10.1186/1743-422X-4-102

    Article  PubMed Central  PubMed  Google Scholar 

  • Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, Kong WP, Yang ZY, Tumpey TM, Nabel GJ (2010) Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2:24ra21

    Google Scholar 

  • WHO (2011) Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccine and other benefits. http://whqlibdoc.who.int/publications/2011/9789241503082_eng.pdf

  • WHO (2012) Recommended composition of influenza virus vaccines for use in the 2013 southern hemisphere influenza season. http://www.who.int/influenza/vaccines/virus/recommendations/201209recommendation.pdf

  • WHO (2013a) Recommended composition of influenza virus vaccines for use in the 2013–2014 northern hemisphere influenza season. http://www.who.int/influenza/vaccines/virus/recommendations/201302_recommendation.pdf

  • WHO (2013b) Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines against avian influenza A(H7N9) virus. As of 23 May 2013 (replaces version of 10 May 2013). http://www.who.int/biologicals/BIOSAFETY_RISK_ASSESSMENT_21_MAY_2013.pdf

  • WHO (2014a) Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. http://www.who.int/influenza/vaccines/virus/201402_h5h7h9h10_vaccinevirusupdate.pdf

  • WHO (2014b) Confirmed human cases of avian influenza A(H7N9) reported to WHO. Report 15—data in WHO/HQ as of 11 March 2014 17:00 GMT+1. http://www.who.int/influenza/human_animal_interface/influenza_h7n9/15_ReportWebH7N9Number_20140311.pdf?ua=1

  • WHO (2014c) Recommended composition of influenza virus vaccines for use in the 2014–2015 northern hemisphere influenza season. http://www.who.int/influenza/vaccines/virus/recommendations/201402recommendation.pdf?ua=1

  • WHO (2014d) Summary of status of development and availability of avian influenza A(H7N9) candidate vaccine viruses and potency testing reagents. http://www.who.int/influenza/vaccines/virus/candidates_reagents/summary_a_h7n9_cvv_20140213.pdf?ua=1

  • WHO Writing Group, Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL, Wairagkar N, Wood J, Zambon M, Zhang W (2012) Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010. Influenza Respir Viruses 6:142–152, e1–5. doi:10.1111/j.1750-2659.2011.00277.x

  • Widjaja L, Ilyushina N, Webster RG, Webby RJ (2006) Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 350:137–145

    Article  CAS  PubMed  Google Scholar 

  • Williams TL, Luna L, Guo Z, Cox NJ, Pirkle JL, Donis RO, Barr JR (2008) Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 26:2510–2520

    Article  CAS  PubMed  Google Scholar 

  • World Intellectual Property Organization (2007) Working paper—patent issues related to influenza viruses and their genes. http://www.wipo.int/export/sites/www/policy/en/global_health/pdf/influenza.pdf

  • Yongfeng H, Fan Y, Jie D, Jian Y, Ting Z, Lilian S, Jin Q (2011) Direct pathogen detection from swab samples using a new high-throughput sequencing technology. Clin Microbiol Infect 17:241–244. doi:10.1111/j.1469-0691.2010.03246.x

    Article  CAS  PubMed  Google Scholar 

  • Zimmer SM, Burke DS (2009) Historical perspective–emergence of influenza A (H1N1) viruses. N Engl J Med 361:279–285. doi:10.1056/NEJMra0904322

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

I thank the synthetic influenza vaccine virus, medical countermeasures, and SAM vaccine teams: P. Suphaphiphat, D. G. Gibson, D. E. Wentworth, T. B. Stockwell, M. A. Algire, N. Alperovich, M. Barro, D. M. Brown, S. Craig, B. M. Dattilo, E. A. Denisova, I. De Souza, M. Eickmann, V. G. Dugan, Hekele, A., S. Bertholet, J. Archer, G. Palladino, L. A. Brito, G. R. Otten, M. Brazzoli, S. Buccato, A. Bonci, D. Casini:, D. Maione, Z.-Q. Qi, J. E. Gill, N. C. Caiazza, J. Urano, B. Hubby, G. F. Gao, Y. Shu, E. De Gregorio, C. W. Mandl, E. C. Settembre, J. B. Ulmer, A. Verma, C. A. Shaw, A. Heckle, K. Banerjee, E. McGurrin, K. Lee, D. Hering, R. Deck, C. Salisbury, M. Mansoura, G. Bodle, L. Solon, M. Hohenboken, N. Kanesa-thasan, S. Fekete, R. May, J. Klock, S. Jauch, O. Brahim, J. Girompini, A. Rak, R. Orlandi, F. Porter, J. Chapman, Y. Cu, C. W. Beard, T. Krucker, D. T. O’Hagan, M. Singh, N. M. Valiante, S. W. Barnett, A. Ferrari, R. C. Gomila, L. Han, C. Judge, S. Mane, M. Matrosovich, C. Merryman, G. A. Palmer, T. Spencer, T. Strecker, H. Trusheim, J. Uhlendorff, Y. Wen, A. C. Yee, J. Zaveri, B. Zhou, S. Becker, A. Donabedian, P. W. Mason, J. I. Glass, A. J. Geall, R. Rappuoli, J. C. Venter. I thank K. Stohr for his careful review of the manuscript and insightful recommendations.

Funding

The work reviewed in this paper was supported in part by BARDA contract HHSO100201000061C and by funds from the Novartis Foundation.

Disclosure

PRD is a Novartis Vaccines employee and a Novartis shareholder.

Author information

Authors and Affiliations

  1. Novartis Vaccines, 350 Massachusetts Ave., Cambridge, MA, 02139, USA

    Philip R. Dormitzer

Authors
  1. Philip R. Dormitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip R. Dormitzer .

Editor information

Editors and Affiliations

  1. Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA

    Michael B. A. Oldstone

  2. IDepartment of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA

    Richard W. Compans

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dormitzer, P.R. (2014). Rapid Production of Synthetic Influenza Vaccines. In: Oldstone, M., Compans, R. (eds) Influenza Pathogenesis and Control - Volume II. Current Topics in Microbiology and Immunology, vol 386. Springer, Cham. https://doi.org/10.1007/82_2014_399

Download citation

Publish with us

Policies and ethics

Search

Navigation